Trial Profile
A Phase 2 Study of Ibrutinib as Neoadjuvant Therapy in Patients With Localized Prostate Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Dec 2023
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; Pharmacodynamics
- 11 Jul 2023 Status changed from active, no longer recruiting to completed.
- 19 Apr 2023 Planned End Date changed from 5 Apr 2023 to 26 Jun 2023.
- 19 Apr 2023 Planned primary completion date changed from 5 Apr 2023 to 26 Jun 2023.